Stockscreener 앱 받기
4.275
6.34%
0.255
전일 마감가:
$4.02
열려 있는:
$4.12
하루 거래량:
56,599
Relative Volume:
0.10
시가총액:
$153.14M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-1.516
EPS:
-2.82
순현금흐름:
$-35.26M
1주 성능:
+6.34%
1개월 성능:
+2.76%
6개월 성능:
+127.39%
1년 성능:
+19.75%
1일 변동 폭
$4.1011
$4.30
1주일 범위
$3.65
$4.30
52주 변동 폭
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.29 | 153.14M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.49 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.81 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.80 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
Protara Therapeutics shares rise on narrower Q4 loss By Investing.com - Investing.com South Africa
Protara Therapeutics shares rise on narrower Q4 loss - Investing.com
Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year - TipRanks
Protara Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 08:21 am EST - Marketscreener.com
Protara Therapeutics, Inc. SEC 10-K Report - TradingView
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - TradingView
Can Protara's 72% Response Rate in Bladder Cancer Trial Transform Treatment Landscape? - StockTitan
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4%Here's What Happened - MarketBeat
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Protara Sets Investor Presentation: What's Next for TARA Pipeline? - StockTitan
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4% – Should You Sell? - Defense World
Certain Pre-Funded warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
Exclusive Healthcare Insights: Protara Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Drop in Short Interest - MarketBeat
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
Geode Capital Management LLC Purchases 29,514 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Highlights Recent Updates and Anticipated 2025 Milestones - The Manila Times
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
XTX Topco Ltd Buys New Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protara Therapeutics Inc 주식 (TARA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Sale |
1.71 |
32,600 |
55,880 |
51,500 |
| Opaleye Management Inc. | 10% Owner |
Sep 09 '24 |
Sale |
1.89 |
36,492 |
69,141 |
54,600 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Sale |
1.77 |
25,500 |
45,110 |
53,100 |
| Opaleye Management Inc. | 10% Owner |
Jul 16 '24 |
Sale |
2.44 |
11,396 |
27,828 |
56,500 |
| Opaleye Management Inc. | 10% Owner |
Jul 11 '24 |
Sale |
2.40 |
47,993 |
115,346 |
60,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 10 '24 |
Sale |
2.31 |
18,061 |
41,685 |
75,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 09 '24 |
Sale |
2.21 |
8,497 |
18,811 |
80,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 01 '24 |
Sale |
2.12 |
8,288 |
17,598 |
87,500 |
| Opaleye Management Inc. | 10% Owner |
Jun 27 '24 |
Sale |
2.26 |
46,574 |
105,169 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 28 '24 |
Sale |
2.07 |
17,994 |
37,334 |
85,000 |
1.28%
0.80%
자본화:
|
볼륨(24시간):